IncellDx, Inc.

Oct 20, 2020

IncellDx to Study Maraviroc, a CCR5 antagonist, in a COVID-19 Phase 2 Clinical Trial

Sep 24, 2020

IncellDx Awarded PD-L1 Detection and Quantification Patent in Tumor Cells and CTCs

Sep 15, 2020

IncellDx and MD Biosciences Sign Definitive Agreement for Commercialization of COVID-19/Cytokine Storm Cytokine Panel and CCR5 Receptor Occupancy in US and EU

Aug 06, 2020

Factorial Diagnostics, IncellDx Sign Exclusive License for Novel in situ Library Prep for Subsequent Next Generation DNA Sequencing